A I; S T R A C T The present studies were undertaken to determine the role, if any, of cyclic 3',5'-adenosine monophosphate (cyclic AMP) as a chemical inducer of rat liver alkaline phosphatase. Cholera enterotoxin, given intravenously to rats, led to a rapid rise in the activity of hepatic adenyl cyclase that was 7A times greater than control values in 6 h. Cyclic AMP levels were also significantlv increased above control values while the activity of cyclic nucleotide phosphodiesterase was unchanged. Hepatic alkaline phosphatase activity was increased 51 times above control in 12 h, but its rise followed that of adenyl cyclase and cyclic AMAP by several hours. Cycloheximide inhibited the rise of hepatic alkaline phosphatase but not that of adenyl cyclase. The administration of glucagon, a known stimulator of hepatic adenyl cyclase, and of dibutyryl cyclic AMP, led to similar striking increases in hepatic alkaline phosphatase activity. This alkaline phosphatase increase was blocked by the prior administration of cvcloheximide. Bile duct ligation, a known stimulator of hepatic alkaline phosphatase activity, failed to produce any significant changes in adenyl cyclase or cyclic AMP. Concomitant treatment of rats with bile duct ligation and cholera enterotoxin or bile duct ligation and glucagon, had no additive effect on the increase in hepatic alkaline phosphatase activity, although the increase occurred earlier. These results suggest that: (a) cyclic AMP may act as an inducer of hepatic alkaline phosphatase; (b) the stimulation of hepatic alkaline phosphatase by cholera enterotoxin is mediated by cyclic AMP; (c) the rise in hepatic alkaline This work has been reported in part, Gastroenterology, 1971. 60: 739 (Abstr.) and Gastroenzterology, 1972. 62: 171 (Abstr.).
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INTRODUCTION
We have previously shown that elevation of the serum alkaline phosphatase following bile duct ligation in rats results from an increase in the activity of hepatic alkaline phosphatase with subsequent leakage of this enzyme into the blood (1) . This increase in hepatic alkaline phosphatase activity is dependent upon de iiovo RNA and protein synthesis (1, 2) . Although enzyme induction is a likely explanation for the increase in alkaline phosphatase activity in the obstructed liver, the precise mechanism by which bile duct ligation increases this enzvrme activity remains uncertain.
Graybill, Kaplan, and Pierce (3) demonstrated that the intravenous injection of purified cholera enterotoxin into dogs produced an elevation of serum levels of alkaline phosphatase of hepatic origin. Recently, the results of several studies have strongly suggested that cholera enterotoxin produces its effects in both intestinal and nonintestinal sites by altering tissue levels of cyclic 3', 5'-adenosine monophosphate (cyclic AMP) (4) (5) (6) (7) (8) (9) . Thus, Kimberg, Field, Johnson, Henderson, and Gershon (4) and others (5, 6) have shown that the enterotoxin is capable of increasing intestinal mucosal adenyl cyclase activity, and it is now clear that this nucleotide is related to the striking enterotoxin-induced alterations in fluid and electrolyte secretion and the associated fulminant diarrhea (7) . Studies concerned with cholera enterotoxin-related enhancement of lipolysis in fat cells (8) and of glycogenolysis in platelets and in liver (9) Chemticals and drugs. Purified cholera enterotoxin' dissolved in sterile water was given intravenously into the tail vein. Animals received either 15 ug of the enterotoxin in a volume of 0.5 ml or a similar volume of isotonic saline (controls). Crystalline glucagon was obtained from Eli Lilly & Co., Indianapolis, Ind., was dissolved in the manufacturer's diluent 2 to a concentration of 1.0 mg/ml, and was administered subcutaneously in order to maximize its effect on hepatic cyclic AMP levels (22) . NM-2'0-dibutyrylcyclic 3',5'-adenosine monophosphate (dibutyryl cyclic AMP) and cycloheximide were purchased from the Sigma Chemical Co., S. Louis, Mo.; the dibutyryl cyclic AMP was diluted in sterile distilled water to a concentration of 2.0 mg/ml, and was administered intraperitoneally. Cycloheximide was diluted in normal saline to a concentration of 1.0 mg/ml and was administered intramuscularly.
Determinations. In order to determine cyclic AMP levels, samples of liver with a wet weight of approximately 100 mg were removed from the animals immediately after sacrifice. The samples were immediately frozen with liquid nitrogen and pulverized. After the liquid nitrogen had evaporated, cyclic AMP was extracted with 5.0 ml of ice-cold 5% trichloroacetic acid containing 3H-cyclic AMP as a 'Purified cholera toxin, prepared according to the procedure described in J. Infect. Dis 6 .0 and 15.0 mg/ml determined as described above. Assays for adenyl cyclase activity were performed by a previously described modification (25) of the method of Krishna, VWeiss, and Brodie (26) . The activity of cyclic nucleotide phosphodiesterase was measured by a method described previously (25) .
The remaining liver, about 2 g, was used for measurement of alkaline phosphatase. (27) . Assays mixtures contained in 1 ml: 600 lumol 2-amino-2-methyl-1 propanol, pH 10.2, 4 ,umol pnitrophenylphosphate, 0.2 umol MgCl2, and 0.001-0.01 International Units of alkaline phosphatase.
RESULTS
Temporal relation between administration of cholera cnterotoxin; and changes in, hepatic enzyme activity. Intravenous administration of cholera enterotoxin, 15 ug/ 100 g body weight, led to a rise in hepatic adenyl cyclase activity and a more delayed increase in hepatic alkaline phosphatase activity (Fig. 1) . Adenyl cyclase activity was significantly elevated 1 h after injection (P < 0.01) and by 6 h it had reached a peak at 7A times control values. Alkaline phosphatase activity began to rise 3 h after enterotoxin administration, but did not become significantly elevated until 1, 2) . On the other hand, the rise in intestinal mucosal adenyl cyclase activity and cyclic AMP levels after exposure to cholera enterotoxin is independent of new protein formation (28) . To determine whether the elevations in hepatic adenyl cyclase and alkaline phosphatase activities following enterotoxin administration depend on intact protein synthesis, enterotoxin-treated animals were studied with and without cycloheximide pretreatment. Fig. 2 shows that cycloheximide pretreatment, in doses that inhibit hepatic protein synthesis by 80% (29) , inhibited the rise in alkaline phosphatase but did not affect the enterotoxin-re-4-I/ § lated elevation of adenyl cyclase activity. s2 1 24 Relation between hepatic cyclic AMP concentration and elevation of hepatic alkaline phosphatase. The preceding results suggested that the increase in hepatic N > cyclic AMP concentration following the administration of cholera enterotoxin might be causally related to the subsequent elevation of hepatic alkaline phosphatase ac-P/ tivity. In order to examine this relationship more closely, 12 24 studies concerned with the effects of glucagon and dibutyryl cyclic AMP on hepatic alkaline phosphatase acadministration of tivity were undertaken. Glucagon in a dose of 0.5 mg ic adenyl cyclase, was administered subcutaneously on two occasions 5 min ups of four con-apart and animals were sacrificed 10, 20, and 60, 360, and at 0, 2, 3, 6, 12, 720 min after the second injection. Alkaline phosphatase f cholera enterocline in a similar activity was unchanged at the early times, but as shown vere sacrificed at in Fig. 3 , it was 2J times control values at 6 h (P < control animals, 0.01). At 10 and 20 min after glucagon administration, there was a marked elevation of hepatic cyclic AMP e m to de levels (P < 0.005 vs. controls, Fig. 4 Figs. 3 and 4 , cycloheximide pretreatment prevented the rise in alkaline phosphatase activity, but did not inhibit the glucagon-induced elevation of cyclic AMP levels. Dibutyryl cyclic AMP administration produced a marked elevation in hepatic alkaline phosphatase activity (P < 0.005, Fig. 3 ). These findings strengthened the postulated relationship between hepatic cyclic AMP concentration and the rise in hepatic alkaline phosphatase activity. Effect of bile duct ligation on cyclic AMP levels and adenyl cyclase activity. The results already presented suggested that the cholera enterotoxin-induced elevation in hepatic alkaline phosphatase activity may be mediated by cyclic AMP. Studies were therefore undertaken to explore the role, if any, of this nucleotide in the bile duct ligation-related increase in alkaline phosphatase activity. As shown in Table I , bile duct ligation failed to produce significant changes in either hepatic adenyl cyclase activity or cyclic AMP levels at 2, 60, 120, 180, or 480 min after operation. Despite the lack of change in adenyl cyclase activity, bile duct ligation was followed by an elevation of alkaline phosphatase activity after an interval similar to that noted in the studies with cholera enterotoxin administration (1, 2). enterotoxin or glucagon administration and bile duct ligation in the same animal would lead to additive effects on hepatic alkaline phosphatase activity. In order to test this possibility, cholera enterotoxin and glucagon were administered to two groups of 10 rats just prior to bile duct ligation. 10 animals were subjected to bile duct ligation alone in order to serve as controls. Five animals in each group were sacrificed 6 and 12 h after ligation. Fig. 5 shows that cholera enterotoxin and glucagon failed to produce an additive effect with bile duct ligation at 12 h (P < 0.05), a time at which the peak elevation of alkaline phosphatase usually occurs. There was, however, a statistically significant increase in alkaline phosphatase activity at 6 h in the bile duct-ligated animals who also received either cholera enterotoxin or glucagon. (1, 2) and the administration of cholera enterotoxin (3) are capable of increasing the activity of hepatic alkaline phosphatase activity. In the case of bile duct ligation, it has also been established that the increased alkaline phosphatase activity is dependent upon intact protein and RNA synthesis (1, 2) . While the data presently available suggest that actual induction of the enzyme may occur following bile duct ligation, further studies will be required to establish the precise mechanism underlying the enhanced alkaline phosphatase activity. The previous demonstration of enhanced hepatic alkaline phosphatase activity following the administration of cholera enterotoxin (3), the more recent evidence implicating cyclic AMP in the mechanism of action of the enterotoxin (4) (5) (6) (7) (8) (9) , and the known effects of hepatic cyclic A1IP as a chemical inducer of other hepatic (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and bacterial (18) (19) (20) (21) enzymes, suggested that this nucleotide may be a mediator involved in increasing hepatic alkaline phosphatase activity. Indeed, the present studies have demonstrated directly that the administration of cholera enterotoxin to rats is followed by an increase in hepatic adenyl cyclase activity with a rise in hepatic cyclic AMP levels, confirming the recent report by Gorman and Bitensky (30) . Furthermore, the present investigations have established that in addition to cholera enterotoxin, the administration of glucagon in doses sufficient to lead to a striking elevation in hepatic cyclic AMP levels also causes a marked increase in rat liver alkaline phosphatase activity. The administration of dibutyryl cyclic AMP is likewise accompanied by a subsequent rise in hepatic alkaline phosphatase. The studies with both glucagon and cholera enterotoxin demonstrate that increased intracellular levels of cyclic AMP precede the rise in alkaline phosphatase activity. In addition, with both agents the prior administration of cycloheximide, an inhibitor of protein synthesis, prevents the rise in alkaline phosphatase activity without influencing the effects of either the enterotoxin or glucagon on cyclic AMP metabolism. Cycloheximide administered in doses sufficient to cause substantial inhibition of protein synthesis failed to influence the effect of the enterotoxin on the adenyl cyclase system in the present studies as well as in others involving small intestinal mucosa (28 bilizing peripheral fatty acids and others which lead to an increase in choline and phosphatidylcholine excretion in bile, is associated with a rise in hepatic alkaline phosplhatase activity. Pekarthy and his associates (31) suggested that the function of alkaline phosphatase was to hydrolyze phosphorylcholine so that choline could be transported across the bile canalicular membrane. They furthermore suggested that the level of enzyme activity was controlled by the quantity of phosphorylcholine available for biliary excretion. At the present time one must remain somewhat reserved about this hypothesis, for recent studies in this laboratory have demonstrated that an increase in hepatic alkaline phosphatase activity is not always associated with an increased excretion of phosphatidyl choline in bile. We have found that there is a marked fall in total bile phospholipid excretion at a time when alkaline phosphatase activity is increased following the administration of cholera enterotoxin. Whether the effects of agents modifying hepatic alkaline phosphatase activity noted in this study as well as in that of Pekarthy et al. (31) are exerted directly on the cyclic AMP metabolic scheme in the hepatocyte or are secondary to peripheral influences of these agents must remain unresolved at the present time. Studies with isolated perfused liver or an organ culture system would be helpful in this regard. Finally, our data, suggestive as they may be, do not establish that the observed rises in alkaline phosphatase activity are necessarily due to enzyme inductions rather than to activation of a preformed enzyme.
